Inotuzumab ozogamicin for the treatment of patients with acute
lymphocytic leukemia

Choudhry, Azhar; O’Brien, Susan

doi:10.1358/dot.2017.53.12.2737934

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Noteworthy were the lower response rates in patients who received InO in salvage chemotherapy after the second relapse in comparison with patients after the first relapse. Among patients with very bad prognostics, InO administration resulted in bone marrow CR rates substantially higher than in patients treated with intensive chemotherapy, although the responses were transient in the second case (102)(103)(104). Weekly versus single-dose clinical experience indicates that weekly InO has similar efficacy, but less systemic toxicity in comparison to single-dose administration.…”

Section: Anti-cd52 Immunotherapymentioning

confidence: 99%

Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia

et al. 2019

View full text Add to dashboard Cite

Background: Therapy for acute lymphoblastic leukemia (ALL) are currently initially efficient, but even if a high percentage of patients have an initial complete remission (CR), most of them relapse. Recent data shows that immunotherapy with either bispecific T-cell engagers (BiTEs) of chimeric antigen receptor (CAR) T cells can eliminate residual chemotherapy-resistant B-ALL cells.Objective: The objective of the manuscript is to present improvements in the clinical outcome for chemotherapy-resistant ALL in the real-life setting, by describing Romania's experience with bispecific antibodies for B-cell ALL. Methods:We present the role of novel therapies for relapsed B-cell ALL, including the drugs under investigation in phase I-III clinical trials, as a potential bridge to transplant. Blinatumomab is presented in a critical review, presenting both the advantages of this drug, as well as its limitations.Results: Bispecific antibodies are discussed, describing the clinical trials that resulted in its approval by the FDA and EMA. The real-life setting for relapsed B-cell ALL is described and we present the patients treated with blinatumomab in Romania.

show abstract

Section: Anti-cd52 Immunotherapymentioning

confidence: 99%

Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Inotuzumab ozogamicin (Besponsa ® ; Pfizer) as a CD22-targeting antibody-drug conjugate (ADC) is approved for adult R/R pre-B ALL, and for the treatment of patients with relapsed or refractory ALL, a group that otherwise has a poor prognosis with standard chemotherapy [ 164 ].…”

Section: Comparison To Other Immunotherapiesmentioning

confidence: 99%

Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment

Sadowski

Olejarz

Basak

2022

IJMS

View full text Add to dashboard Cite

Genetically engineered T and NK cells expressing a chimeric antigen receptor (CAR) are promising cytotoxic cells for the treatment of hematological malignancies and solid tumors. Despite the successful therapies using CAR-T cells, they have some disadvantages, such as cytokine release syndrome (CRS), neurotoxicity, or graft-versus-host-disease (GVHD). CAR-NK cells have lack or minimal cytokine release syndrome and neurotoxicity, but also multiple mechanisms of cytotoxic activity. NK cells are suitable for developing an “off the shelf” therapeutic product that causes little or no graft versus host disease (GvHD), but they are more sensitive to apoptosis and have low levels of gene expression compared to CAR-T cells. To avoid these adverse effects, further developments need to be considered to enhance the effectiveness of adoptive cellular immunotherapy. A promising approach to enhance the effectiveness of adoptive cellular immunotherapy is overcoming terminal differentiation or senescence and exhaustion of T cells. In this case, EVs derived from immune cells in combination therapy with drugs may be considered in the treatment of cancer patients, especially effector T and NK cells-derived exosomes with the cytotoxic activity of their original cells.

show abstract

“…Bispecific antibodies [6][7][8][9][10], antibody-drug conjugates [11], sugar chain-modified antibodies [12][13][14][15] and low molecular weight antibodies [6,16] are now being emphasized as next-generation products. Some bispecific antibodies and antibody-drug conjugates are already on the market, with emicizumab [17] as an example of the former, and gemtuzumab ozogamicin [18], inotuzumab ozogamicin [19] and brentuximab vedotin [20] featuring in the latter.…”

Section: Therapeutic Monoclonal Antibodiesmentioning

confidence: 99%

Future Perspectives of Therapeutic Monoclonal Antibodies

Tsumoto¹,

Isozaki²,

Yagami³

et al. 2019

Immunotherapy

View full text Add to dashboard Cite

Attention to therapeutic monoclonal antibodies has been dramatically increasing year by year. Their highly specific targeting of antigens can provide very effective medical treatment, and the advent of moleculartargeting medicine is allowing development of a new generation of therapeutic agents. However, there is one critical obstacle to overcome. Most of the established therapeutic monoclonal antibodies have specificity for the primary structures of target antigens, although all proteins harbor original native intact structures for their own specific functions. Stereo-specific monoclonal antibodies recognizing conformational structures of target antigens may thus offer a markedly more versatile approach. Their application may change the very concepts underlying use of therapeutic antibodies.

show abstract

Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia

Cited by 6 publications

References 0 publications

Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia

Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia

Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment

Future Perspectives of Therapeutic Monoclonal Antibodies

Contact Info

Product

Resources

About